The Efficacy and Safety of the Chinese Herbal Formula, JTTZ, for the Treatment of Type 2 Diabetes with Obesity and Hyperlipidemia: A Multicenter Randomized, Positive-Controlled, Open-Label Clinical Trial
Table 1
Baseline characteristics of participants receiving JTTZ formula and metformin.
Characteristics
JTTZ group ()
MET group ()
values
General information
Age (years)
52.82 ± 9.01
52.90 ± 8.52
0.922
Sex (male/female)
104/111
98/101
0.859
Past medical history (no/yes)
77/138
83/116
0.218
Current medications (no/yes)
125/90
128/71
0.197
Physical examinations
Systolic BP (mmHg)
129.55 ± 12.36
131.11 ± 11.95
0.196
Diastolic BP (mmHg)
82.80 ± 8.03
82.62 ± 8.24
0.823
Heart rate (beat/min)
74.80 ± 8.47
73.31 ± 7.84
0.064
Height (cm)
165.81 ± 8.24
165.41 ± 8.80
0.638
Weight (kg)
77.82 ± 12.08
76.86 ± 12.06
0.421
BMI (kg/m2)
28.24 ± 3.31
28.01 ± 3.22
0.485
Waist circumference (cm)
97.25 ± 8.09
97.47 ± 9.24
0.800
Hip circumference (cm)
105.05 ± 7.14
105.31 ± 7.36
0.717
Efficacy indicators
HbA1c (%)
8.26 ± 1.35
8.28 ± 1.33
0.908
FPG (mmol/L)
9.64 ± 2.59
9.56 ± 2.39
0.744
2 h PG (mmol/L)
16.76 ± 4.93
17.00 ± 4.72
0.610
Fasting insulin (pmol/L)
103.89 ± 97.73
100.88 ± 131.62
0.796
TC (mmol/L)
5.46 ± 1.24
5.56 ± 1.36
0.412
TG (mmol/L)
3.43 ± 2.83
3.18 ± 2.14
0.321
LDL-C (mmol/L)
3.21 ± 0.96
3.29 ± 0.90
0.429
HOMA-IR
1.58 ± 0.72
1.5 ± 0.75
0.286
HOMA-β
3.73 ± 0.76
3.63 ± 0.78
0.176
Cardinal symptoms
Total symptom points
11.03 ± 4.93
10.78 ± 4.63
0.598
Data presented as mean ± standard deviation. Current medications: participants were taking or not taking other medications during the study period; BMI: body mass index; HbA1c: glycosylated hemoglobin; FPG: fasting plasma glucose; 2 h PG: 2 h postprandial plasma glucose; TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HOMA-IR: insulin resistance index; HOMA-β: β cell function index.
